-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PyKF/PCedPQ9mbvq0JCWXYOofu4ePPkB/zsLx71VThvoWOAtrvctEb8FZRCJJ0ww +QMlYCm5+67k8GwXevgdmQ== 0000062391-98-000007.txt : 19980402 0000062391-98-000007.hdr.sgml : 19980402 ACCESSION NUMBER: 0000062391-98-000007 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 19980401 SROS: NASD GROUP MEMBERS: HMR PHARMA, INC. GROUP MEMBERS: HOECHST MARION ROUSSEL INC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LYNX THERAPEUTICS INC CENTRAL INDEX KEY: 0000913275 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 943161073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-45671 FILM NUMBER: 98584948 BUSINESS ADDRESS: STREET 1: 3832 BAY CENTER PL CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5106709300 MAIL ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 74545 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G 1 LYNX THERAPEUTICS 13G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LYNX THERAPEUTICS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.01 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 551812 30 8 ----------------- (CUSIP Number) *The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would later the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) =========================================================================== Page 1 of 10 Exhibit Index is located at page 9 2 CUSIP No. 551812 30 8 ___________________________________________________________________________ 1) Name of Reporting Person and its Hoechst Marion Roussel, Inc. I.R.S. Identification Number 44-0565557 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 400,000* Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 400,000* Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 400,000* by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 6.36% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ *Does not include an undetermined number of shares the reporting person is obligated to purchase upon the happening of a future event. 3 CUSIP No. 551812 30 8 13G ___________________________________________________________________________ 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 400,000* Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 400,000* Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 400,000* by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 6.36% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ *Does not include an undetermined number of shares the reporting person is obligated to purchase upon the happening of a future event. 4 CUSIP No. 551812 30 8 13G This Statement on Schedule 13G (the "Schedule 13G") with respect to the Common Stock of Lynx Therapeutics, Inc. (the "Issuer"), is filed jointly by Hoechst Marion Roussel, Inc., a Delaware corporation ("HMRI"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), to (1) replace the Schedule 13D previously filed by the reporting persons, who have determined pursuant to SEC Rule 13d-1(h) that the provisions of paragraphs (e), (f), and (g) of Rule 13d-1 do not apply; and (2) to report the automatic conversion of the 40,000 shares of Series D Convertible Preferred Stock to 400,000 shares of Common Stock (one-for-ten basis) on March 31, 1998. ITEM 1(a). NAME OF ISSUER: - ---------- --------------- Lynx Therapeutics, Inc. ITEM 1(b). ADDRESS OF ISSUER S PRINCIPAL EXECUTIVE OFFICES: - ---------- ------------------------------------------------ 3832 Bay Center Place Hayward, CA 94545 ITEM 2(a). NAME OF PERSON FILING: - ---------- ---------------------- Hoechst Marion Roussel, Inc. HMR Pharma, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ---------- ------------------------------------------------------------ Hoechst Marion Roussel, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - ---------- ------------ Delaware As To Both Hoechst Marion Roussel, Inc. And HMR Pharma, Inc. ITEM 2(d). TITLE OF CLASS OF SECURITIES: - ---------- ----------------------------- Common Stock, $.01 Par Value 5 CUSIP No. 551812 30 8 13G ITEM 2(e): CUSIP NUMBER: - ---------- ------------- 551812 30 8 ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR 13D-2(b): - ------- ------------------------------------------------------- Not Applicable ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: 400,000 Shares Of Common Stock, effective 03/31/98 upon automatic conversion of 40,000 Shares of Series D Convertible Preferred Stock on a one-for-ten basis. (b): PERCENT OF CLASS: 6.36% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 400,000* (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the 400,000* disposition of: (iv) Shared power to dispose or to direct the 0 disposition of: *Does not include an undetermined number of shares the reporting person is obligated to purchase upon the happening of a future event. ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS - ------- --------------------------------------------- Not Applicable 6 CUSIP No. 551812 30 8 13G ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. - ------- ---------------------------------------------------------------- Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH - ------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY --------------------------------------------------------------- Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP - ------- --------------------------------------------------------- Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. - ------- ------------------------------- Not Applicable ITEM 10. CERTIFICATION. - -------- -------------- Not Applicable 7 CUSIP No. 551812 30 8 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 31, 1998 --------------------------------- (Date) HOECHST MARION ROUSSEL, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 8 CUSIP No. 551812 30 8 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 31, 1998 --------------------------------- (Date) HMR PHARMA, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 9 CUSIP No. 551812 30 8 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated March 10 31, 1998, by and between Hoechst Marion Roussel, Inc. and HMR Pharma, Inc. EX-99 2 EXHIBIT 99.A TO LYNX THERAPEUTICS 13G 10 CUSIP No. 551812 30 8 13G EXHIBIT 99.A ------------ AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G and all subsequent amendments thereto executed by both of us are filed on behalf of each of us. HOECHST MARION ROUSSEL, INC. March 31, 1998 /s/ Rebecca R. Tilden - --------------------------- ------------------------------------- (Date) (Name and Title) Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. March 31, 1998 /s/ Rebecca R. Tilden - --------------------------- ------------------------------------- (Date) (Name and Title) Rebecca R. Tilden Vice President and Secretary -----END PRIVACY-ENHANCED MESSAGE-----